Background:
People with HIV take drugs to keep the amount of virus in their body low. One type of these drugs, called integrase strand transfer inhibitors (INSTIs), can cause weight gain over time. Weight gain can cause diabetes, heart disease, and other serious issues. Researchers want to understand how INSTIs cause weight changes.
Objective:
To characterize the change in plasma metabolite profile that 4 weeks of each treatment may induce in the absence of HIV infection
Eligibility:
Healthy people aged 18 to 55.
Design:
Participants will be screened in the outpatient clinic. They will have a physical exam and blood tests. They will have a nutritional assessment and tests of their heart function.
Participants will be randomized to one of four oral treatments: Tenofovir Disoproxil Fumarate TDF/Viread, Tenovovir Alafenamide TAF/Vemlidy, Dolutegravir DTG/Tivicay, or both TAF and DTG taken together for 4 weeks.
Participants will have a Day 0 visit for the Lead-In Baseline visit for an exam and blood tests and continuous glucose monitor placement.
Participants will return in 2wks or Day 14/Wk 2 for a DEXA (dual-energy X-ray absorptiometry). DEXA is a kind of X-ray that measures body fat and bone density. Optional adiopse (fat) tissue biopsy in the abdomen, and optional microbiome specimen collections. Continuous glucose monitor changed. Oral once a day dose medication will be started with education.
Participants will return in 2wks or Day 28/Wk 4 for exam, labs, and continuous glucose monitor changed.
Participants will return in 2wks or Day 42/Wk 6 for final exam, labs, repeat DEXA scan, repeat adipose tissue biopsy, and microbiome specimen collections.

Start Date19 Jul 2026

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

NCT07124559

/ Not yet recruitingPhase 1/2IIT

Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

This study aims to find the proposed dose of Rifapentine (RPT) taken once daily with Isoniazid (INH) for 28 days to prevent tuberculosis (TB). The study will take place at multiple locations and children under 13 years old will be divided into two groups: one group will include children without HIV, and the other group will include children with HIV who are on antiretroviral treatment. Up to 144 children will participate, and participants in each group will be followed for 24 weeks.

Start Date15 Jul 2026

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

[+1]

NCT06805656

/ Not yet recruitingPhase 2IIT

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Use of Antiretrovirals

A modern and urgent challenge in fighting HIV infection is to achieve sustained HIV remission without the use of antiretrovirals. The investigators' preliminary data indicate that the use of combined strategies to mitigate the HIV proviral reservoir size among individuals with suppressive antiretroviral treatment achieved unprecedented results in the reduction of HIV DNA present in these cells and in the reduction of CD4 + and CD8 + T cell activation. Combined interventions include intensified antiretroviral treatment to mitigate residual HIV replication, use of a histone deacetylase inhibitor to interrupt viral latency, use of an anti-proliferative medication to reduce long-lived T cells that harbor HIV and a personalized dendritic cell therapy vaccine to eliminate cells with latent HIV infection or cells present in viral sanctuaries. Due to the good results obtained in the exploratory stage of the project, the investigators propose to expand it by recruiting a larger number of patient to confirm the previously obtained results and to generate new insights related to the mechanisms involved in viral latency, latency disruption and the effects of analytical treatment interruption of antiretrovirals among patients undergoing all above mentioned interventions.

Start Date01 Jul 2026

Sponsor / Collaborator

Universidade Federal De Sao Paulo

[+1]

100 Clinical Results associated with Dolutegravir Sodium

100 Translational Medicine associated with Dolutegravir Sodium

100 Patents (Medical) associated with Dolutegravir Sodium

3,458

Literatures (Medical) associated with Dolutegravir Sodium

31 Dec 2026·ANNALS OF MEDICINE

Efficacy and metabolic outcomes of switching from an INSTI-based triple-drug regimen to dolutegravir/lamivudine in treatment-experienced HIV-1-infected patients: a 48-week real-world study

Article

Author: Li, Qisui ; Zhang, Wei ; Yuan, Jing ; Deng, Changgang

BACKGROUND:

Real-world data on switching from INSTI-based triple therapy to DTG/3TC in the Chinese population are lacking.

METHODS:

This retrospective study included 214 treatment-experienced patients with HIV from Chongqing Public Health Medical Center (2021-2022) on an INSTI-based triple-drug regimen for ≥6 months who switched to DTG/3TC for >12 months. Patients with pre-existing metabolic diseases were excluded. Participants were categorized: INSTI+TAF-free (n = 100, prior TDF/AZT/ABC), INSTI+TAF (n = 56, prior BIC/FTC/TAF), and INSTI+TAF+COBI (n = 58, prior EVG/c/FTC/TAF). Virological, immunological, and metabolic parameters were assessed at weeks 24 and 48.

RESULTS:

The INSTI+TAF+COBI group was significantly older (p=0.000). Virological suppression rates (<50 copies/mL) were high at switch (93%, 85.7%, 91.4%). The INSTI+TAF+COBI group had lower eGFR and higher TG, TC, HDL, and LDL at baseline (p < 0.05). After switching, virological suppression remained high (≥90%) at weeks 24 and 48. CD4+ T-cell increases showed no significant intergroup differences. Metabolic changes differed: TC changes were 0.57 mmol/L (IQR: -0.19-0.91) in INSTI+TAF-free, -0.09 mmol/L (-0.47-0.71) in INSTI+TAF, and -0.25 mmol/L (-0.99-0.33) in INSTI+TAF+COBI. LDL changes were 0.23 mmol/L (-0.23-0.67), -0.15 mmol/L (-0.39-0.01), and -0.18 mmol/L (-0.71-0.10), respectively. TC and LDL changes differed significantly among groups (p < 0.05).

CONCLUSION:

Switching to DTG/3TC maintained virological suppression and stable immunological outcomes. Patients previously on TAF-containing regimens demonstrated greater metabolic benefits than those on TAF-free regimens, possibly related to baseline TDF effects, requiring further confirmation.

31 Dec 2026·ASN Neuro

Exposure to Frontline Antiretroviral Dolutegravir Disrupts Oligodendrocyte Development Across Differentiation Stages

Article

Author: Cruz-Berríos, Melanie ; Grinspan, Judith B. ; Putatunda, Raj ; Romer, Micah A. ; Jeffries, Marisa A. ; Jordan-Sciutto, Kelly L. ; Singhal, Anushka

The use of antiretroviral (ART) treatment during pregnancy has dramatically reduced rates of perinatally-acquired human immunodeficiency virus 1 (HIV-1) infection to <1% in the United States. Despite this success, we have limited knowledge of how ART drugs that cross the placental barrier affect fetal development, particularly in the central nervous system (CNS). During gestation, large populations of oligodendroglia are produced that are responsible for critical postnatal CNS myelination enabling appropriate neurological function. Previous studies have shown that antiretrovirals impair oligodendrocyte (OL) differentiation leading us to hypothesize that OL maturation might be inhibited by exposure to a frontline ART drug cocktail (Triumeq®) prescribed during pregnancy containing dolutegravir (DTG), abacavir (ABC), and lamivudine (3TC). In this study, we demonstrated that exposing primary rat oligodendrocyte precursor cells (OPCs) and OLs to the Triumeq drug combination decreased OL maturation and myelin protein production in a concentration-dependent manner, and that DTG was solely responsible. Regardless of the timing of exposure during OL development, a high concentration of DTG inhibited OL maturation. Bulk RNA sequencing revealed transcriptional changes after DTG exposure related to a variety of cellular mechanisms, including cellular responses to stress pathways, amino acid starvation, and mitochondrial dysfunction. Although we found that DTG robustly activated the integrated stress response (ISR), attempted rescue experiments showed that DTG primarily inhibits OL maturation independently of the ISR. Collectively, our novel data on DTG underscore the necessity of investigating how ART drugs that are administered during pregnancy and cross the placental barrier can affect fetal CNS development.

31 Dec 2026·HIV Research & Clinical Practice

Longitudinal analysis of viral suppression before, during, and after pregnancy among women on antiretroviral therapy in Uganda: six-year real-world experience

Article

Author: Mumbere, Iving ; Emunyu, Jude ; Sserunjogi, Conrad ; Namasambi, Sharon ; Kyomuhangi, Brendah ; Nakawesi, Jane ; Ankunda, Collins

INTRODUCTION:

This study evaluated the effectiveness of antiretroviral therapy (ART) and associated factors on viral suppression before, during, and after pregnancy (maternal timeline).

METHODS:

We conducted a cohort study, retrospectively reviewing records of 1291 pregnant and breastfeeding women on ART. Descriptive statistics summarised the demographics and clinical characteristics. Chi-square, Fisher's exact, and generalised estimating equations were used to assess variations in viral suppression across the maternal timeline.

RESULTS:

ART regimens comprised 62.5% dolutegravir (DTG)-, 28.8% efavirenz (EFV)-, 4.5% nevirapine (NVP)-, and 4.2% protease inhibitor (PI)-based therapy. Viral suppression rates before, during, and after pregnancy were DTG- (95.0%, 94.6%, 95.7%), EFV- (94.9%, 94.2%, 93.6%), NVP- (93.1%, 94.7%, 93.5%), and PI-based (79.6%, 88.0%, 85.7%). ART regimens varied in effectiveness, with statistical significance observed before (p < 0.001) and after (p = 0.018), but not during pregnancy (p = 0.678). PI-based regimens showed higher risk of non-suppression in the non-adjusted model (IRR = 3.20, 95% CI: 1.63-6.30, p = 0.001). In the adjusted model, poor adherence (aIRR = 7.80, 95% CI: 2.54-23.90, p < 0.001), fair adherence (aIRR = 5.03, 95% CI: 1.11-22.86, p = 0.036), second-line ART (aIRR = 3.14, 95% CI: 1.75-5.62, p < 0.001), and third-line ART (aIRR = 8.48, 95% CI: 1.82-39.43, p = 0.006) remained significant.

CONCLUSION:

ART effectiveness showed variation before and after, but not during pregnancy. EFV- and NVP-based regimens achieved suppression rates comparable to DTG across maternal timelines, with the exception of PI-based regimens. Adherence and ART drugs influence outcomes more than regimen choice alone, with good adherence essential for optimal maternal outcomes.

165

News (Medical) associated with Dolutegravir Sodium

22 Jun 2026

·viivhealthcare.com

ViiV HEALTHCARE ADVANCES PAEDIATRIC HIV REGULATORY SUBMISSIONS WITH FDA PRIORITY REVIEW FOR TIVICAY PD AND EMA VALIDATION OF MARKETING APPLICATION FOR TIVICAY

For Media and Investors only Marketing applications seek to expand the use of Tivicay PD and Tivicay (dolutegravir) to newborns from birth, supported by age-specific dosing and clinical data If approved, dolutegravir would be the first second-generation integrase inhibitor available for newborns Newborns have historically had the fewest HIV treatment options, with limited access to modern regimens London, 22 June 2026 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) to extend the use of Tivicay PD (dolutegravir (DTG)) to newborns from birth. The FDA has granted Priority Review for this application and assigned a Prescription Drug User Fee Act (PDUFA) action date of August 25, 2026. The European Medicines Agency (EMA) has also validated the marketing application for Tivicay, as the company continues to focus on addressing one of the most persistent gaps in care by expanding age-appropriate treatment options for the earliest stage of life.1 DTG is a second-generation integrase strand transfer inhibitor (INSTI) with a higher barrier of resistance than previous generations. Without early diagnosis and treatment, HIV can progress rapidly in infants, with around 50% of untreated infants living with HIV dying by age two, underscoring the importance of treatment options from birth.2 Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said: “Early HIV treatment can help shape a child’s future, yet newborns have historically had the fewest age-appropriate treatment options. ViiV Healthcare has a long-standing commitment to changing that and helping ensure children are not left behind in HIV innovation. These regulatory submissions are a key step toward bringing an innovative, INSTI-based treatment to newborns from birth.” The submissions to the FDA and the EMA are supported by data from the IMPAACT 2023 study and pharmacokinetic (PK) modelling incorporating additional paediatric data, demonstrating that DTG achieved target PK exposures in term neonates with no new safety findings observed, compared with older paediatric populations. These submissions build on recent announcements for dolutegravir/lamivudine (DTG/3TC) that the EMA had validated the marketing application seeking approval to extend use to younger age groups, alongside submission of a New Drug Application to the FDA. About Tivicay and Tivicay PD Tivicay and Tivicay PD contain dolutegravir, an integrase strand transfer inhibitor for use in combination with other antiretroviral agents for the treatment of HIV. Integrase inhibitors inhibit HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle. Please consult the full Prescribing Information here. Trademarks are owned by or licensed to the ViiV Healthcare group of companies. About IMPAACT The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is a global collaboration of investigators, institutions, community representatives, and other partners with a mission to improve health outcomes in infancy, childhood, adolescence, pregnancy, and postpartum among those who are impacted by or living with HIV, tuberculosis, and other related complications through the conduct of high-quality clinical trials. IMPAACT’s vision and overall goal is to end the worldwide HIV epidemic among these populations. To achieve this goal, the IMPAACT Network evaluates novel and durable treatments for HIV, TB, and related diseases and conditions, strategies for antiretroviral treatment (ART)-free remission, and strategies to prevent and manage neuropsychological and mental health complications of HIV and its treatment. Overall support and funding for IMPAACT is provided by the National Institute of Allergy and Infectious Diseases (NIAID), with support and co-funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Institute of Mental Health (NIMH), all components of the United States National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. For more information, please visit: www.impaactnetwork.org. About the National Institutes of Health (NIH) NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit: www.nih.gov. About ViiV Healthcare ViiV Healthcare is a global specialist HIV company established in November 2009 with GSK (LSE: GSK) and Shionogi as current shareholders. The company is dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention. ViiV Healthcare’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit viivhealthcare.com. About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com. Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q1 Results for 2026. Registered in England & Wales: GSK plc ViiV Healthcare Limited No. 3888792 No. 06876960 Registered Office: 79 New Oxford Street ViiV Healthcare Limited London GSK Medicines Research Centre WC1A 1DG Gunnels Wood Road, Stevenage United Kingdom SG1 2NY References: For our corporate press office, email: Kate Senter OR call +44 7796 707446 For US-specific media enquiries, email: Rachel Jaikaran OR call +1 9193578932 Reporting of side effects If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine. If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here. Connect with us ViiV Healthcare 79 New Oxford Street London United Kingdom WC1A 1DG Tel: +44 20 8047 5000 Contact us Terms of use Cookie policy Privacy notice Modern Slavery Statement Sitemap All our locations Our Clinical Trial Register GSK.com Carbon Reduction Plan Corporate ethics and compliance Social Media at ViiV Healthcare NP-GBL-HVX-COCO-230027 April 2026 ©2021 ViiV Healthcare group of companies. All rights reserved. ViiV Healthcare UK Limited. Registered in England and Wales No. 06990358.

Priority ReviewClinical Study

15 Jun 2026

·www.adalvo.com

Adalvo advances European filing for generic dolutegravir

Adalvo is submitting its dossier for generic dolutegravir film-coated tablets through the European DCP. Dolutegravir — marketed as Tivicay (ViiV Healthcare) — is a cornerstone of WHO-recommended first-line HIV treatment regimens. Adalvo's generic covers 10mg, 25mg, and 50mg strengths, supporting treatment across a broad patient population. An estimated 39 million people worldwide are living with HIV, with sustained access to affordable antiretroviral therapy remaining a global healthcare priority. IQVIA data shows dolutegravir generated $478.6M in European sales in 2025, reflecting its continuing clinical and commercial significance. The completed dossier reflects Adalvo's ability to develop complex, technically demanding therapies, and adds further depth to the company's anti-infectives portfolio. Adalvo's dolutegravir programme is targeted at Day-1 launch opportunities in European and international markets, with the goal of expanding patient access to a therapy that remains at the heart of HIV care. To contact us about licensing details, or to view our full range of anti-infective therapies, email us: enquiry@adalvo.com

09 Jun 2026

·www.fiercebiotech.com

GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer

GSK CEO Luke Miels said the deal “will strengthen our operating profit ... through the dolutegravir loss of exclusivity period.”\n GSK has struck a deal to buy Nuvalent for $10.6 billion, securing two near-approval cancer therapies that could challenge products from Roche, Pfizer and other drugmakers. The FDA is set to rule on whether to approve Nuvalent’s ROS1 inhibitor zidesamtinib in September and reach a decision on the biotech’s ALK inhibitor neladalkib in November. With two near-approval assets, plus a phase 1 HER2 inhibitor and preclinical programs, the deal offers near-term growth drivers to ease the pressure GSK could face as generics erode sales of a key HIV drug from 2028 to 2030.“Subject to FDA approvals, the acquisition will deliver revenue growth from 2027. This is what our investors have been asking,” GSK CEO Luke Miels said on a call with the media early Tuesday morning. “It will strengthen our operating profit for GSK through the dolutegravir loss of exclusivity period.”Nuvalent filed for FDA approval of zidesamtinib in ROS1-positive non-small cell lung cancer (NSCLC) patients who have previously received a tyrosine kinase inhibitor (TKI). Before accepting GSK’s offer, the biotech said (PDF) it planned to apply to expand the label in the second half of the year to include patients without prior TKI exposure.Zidesamtinib could pose a threat to Pfizer’s TKI inhibitor Xalkori, which Nuvalent named as the first-line standard of care. Treatment guidelines also recommend (PDF) Roche’s Rozlytrek, Bristol Myers Squibb’s Augtyro and Nuvation Bio’s Ibtrozi, especially against brain metastases. Nuvalent has identified improved durability and reduced central nervous system side effects as ways to differentiate zidesamtinib.The FDA is reviewing neladalkib in TKI-pretreated, ALK-positive NSCLC. Nuvalent is enrolling patients in a phase 3 trial that is pitting the ALK inhibitor against Roche’s Alecensa in TKI-naive patients. Alecensa is the first-line standard of care and Pfizer’s Lorbrena is the preferred second-line treatment, according to Nuvalent. Miels named a recent seven-year analysis of Pfizer’s phase 3 Crown study as a driver of GSK\'s interest in neladalkib. The data showed Pfizer’s Lorbrena “has very good efficacy but a very, very difficult side effect profile to manage,” Miels said. Because patients are often relatively young, the downsides to a drug that impacts their ability to care for their kids and lead active lives are particularly severe, Miels said.The duration of treatment factored into GSK’s valuation of Nuvalent. The target mutations are found in a small subset of patients—about 3% to 5% of people with NSCLC are ALK-positive—but patients who are eligible for treatment spend longer on the drugs than is typical for many cancers. That means there are “very long tails to these products,” Miels said. About 1% to 3% of patients have ROS1 mutations. GSK sees “multiblockbuster potential” for zidesamtinib and neladalkib, leading it to agree to pay $124 a share to buy the biotech. Nuvalent’s stock closed at $88.49 on Monday. The outlay is well beyond the $2 billion to $4 billion deal range that Miels targeted after becoming CEO early this year. Yet the GSK leader maintained that the Nuvalent buyout is in line with the types of deals the company has been pursuing and striking. The difference is that instead of paying up to $4 billion for a biotech with one attractive asset, GSK is paying $10.6 billion for a company with multiple molecules of interest. “If you take apart the components, it\'s consistent with our approach so far,” Miels said. If zidesamtinib or neladalkib wins FDA approval, the deal will accelerate GSK’s entry into lung cancer and provide a potential launchpad for its B7-H3 antibody-drug conjugate (ADC) risvutatug rezetecan. GSK started a phase 3 trial of the ADC in small cell lung cancer last year.

Phase 3AcquisitionPhase 1Drug ApprovalADC

100 Deals associated with Dolutegravir Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D10113	Dolutegravir Sodium	J05AX12	DB08930

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	ViiV Healthcare Co.	12 Aug 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pregnancy	Phase 3	South Africa	ViiV Healthcare Ltd.	14 Mar 2017
Pregnancy	Phase 3	Uganda	ViiV Healthcare Ltd.	14 Mar 2017
Pulmonary Tuberculosis	Phase 3	Argentina	GSK Plc	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	Brazil	ViiV Healthcare Ltd.	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	Mexico	GSK Plc	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	Peru	GSK Plc	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	Russia	GSK Plc	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	South Africa	GSK Plc	23 Jan 2015
Pulmonary Tuberculosis	Phase 3	Thailand	GSK Plc	23 Jan 2015
Tuberculosis	Phase 3	Argentina	GSK Plc	23 Jan 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03016533 (CTgov)	Phase 3	HIV Infections	100	Dolutegravir film-coated tablets (Dolutegravir (DTG))	gbussqzqro = junuqzjpok wxqnohhwyi (pvhywvievn, oovxbeqnht - kfwlsqmmfe) View more	-	05 Feb 2026
				ABC/DTG/3TC film-coated dispersible tablets (Abacavir/Dolutegravir/Lamivudine(ABC/DTG/3TC))	gbussqzqro = fqkbcepryz wxqnohhwyi (pvhywvievn, xszchycbjo - guoldxmnpd) View more
GS-US-380-1844，ALLIANCE (Pubmed)	-	HIV Infections	2,622	多替拉韦+恩曲他滨+丙酚替诺福韦	zswclrojsl(buyjvnjbxy) = mdevtawmae ommgremiod (zspcmqfpzo ) View more	Positive	18 Nov 2024
				多替拉韦	zswclrojsl(buyjvnjbxy) = fwduhkzxiy ommgremiod (zspcmqfpzo ) View more
NCT03048422 (IMPAACT 2010 (VESTED), Pubmed \| J Acquir Immune Defic Syndr)	Phase 3	bone mineral density \| creatinine clearance	-	Dolutegravir + emtricitabine/tenofovir alafenamide (DTG + FTC/TAF)	rdorpeeabw(orgqlpdzdi) = hebqabhysa lrqbwbcwsn (bplxojlqxg )	Positive	01 Oct 2024
				Dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG + FTC/TDF)	rdorpeeabw(orgqlpdzdi) = ytazqbosvz lrqbwbcwsn (bplxojlqxg )
NCT03249181 (DolPHIN-2, Pubmed \| J Antimicrob Chemother)	Phase 3	HIV Infections	268	Dolutegravir-based regimen	wslmqwcwii(vdgkqiqonz) = zmxbzbytaw utprbpiyjq (meyaojvhts ) View more	Negative	03 Sep 2024
NCT03991013 (ARTIST, CTgov)	Phase 2	HIV Infections	192	tenofovir+Dolutegravir+lamivudine (Stage 2: Supplementary Dose)	mydqybbkjf = ztszsmqsey eamyczwxzp (wxatwmmhim, lxcgwvbtnx - vakwesnudo) View more	-	09 Aug 2024
				Placebo (Stage 2: Placebo Dose)	mydqybbkjf = nwyxntxnmb eamyczwxzp (wxatwmmhim, jjfybqvfwe - hpbmrraymv) View more
NCT04272242 (CTgov)	Phase 2	Latent Tuberculosis \| HIV Infections	37	Antiretroviral Therapy (ART)+Dolutegravir (DTG)+Rifapentine (RPT)+Isoniazid (INH)	wvosiolvvy(pklwysqxvr) = ystdmzzkxj lejzuvqixt (bvjjolbjht, edldiivixo - oztrfsddqm) View more	-	09 Aug 2024
NCT03017872 (D2EFT, Pubmed)	Phase 4	HIV Infections Second line HIV RNA load	828	ritonavir-boosted darunavir plus two NRTIs	ymlndbkhgk(roszaujpay) = sudiearzmn bdkgrdceez (abhdrvlick )	Positive	01 Jul 2024
				ritonavir-boosted darunavir plus dolutegravir	ymlndbkhgk(roszaujpay) = bmluiialsf bdkgrdceez (abhdrvlick )
NCT04857892 (CTgov)	Phase 1	HIV Infections	41	GSK3640254+DTG (Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg)	zbnkdplrkm(djicgwzzcn) = usbtqyksvn mcwpxibryp (xkvavqwepw, 46.8) View more	-	12 Mar 2024
				GSK3640254+DTG (Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet))	zbnkdplrkm(djicgwzzcn) = japcrtgokb mcwpxibryp (xkvavqwepw, 36.6) View more
NCT01837277 (IDEA, CTgov)	Phase 2/3	Acquired Immunodeficiency Syndrome	186	Dolutegravir 50 mg (Dolutegravir)	gkcpgsivoz = jrzqwhiwkg fhawatvedh (mhbiwolvsu, eiozzevber - lgucmimgyq) View more	-	14 Dec 2023
				Efavirenz (Efavirenz)	gkcpgsivoz = fymwrapavd fhawatvedh (mhbiwolvsu, vwjfilmbex - qtuossehyl) View more
NCT02777229 (NAMSAL-ANRS-12313, Pubmed \| Open Forum Infect Dis)	Phase 3	HIV Infections First line	613	Dolutegravir (DTG) 50mg with Tenofovir disoproxil fumarate and Lamivudine (TDF/3TC)	fdzwjvishh(athewtznsf) = qxzlmyimee kaugqxkwep (fjjrcfyozb ) View more	Positive	01 Dec 2023
				Efavirenz 400 mg (EFV400) with Tenofovir disoproxil fumarate and Lamivudine (TDF/3TC)	fdzwjvishh(athewtznsf) = vtgvzehdrq kaugqxkwep (fjjrcfyozb ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis